Literature DB >> 16395703

CDKN2A common variant and multi-organ cancer risk--a population-based study.

Tadeusz Debniak1, Rodney J Scott, Tomasz Huzarski, Tomasz Byrski, Andrzej Rozmiarek, Boguslaw Debniak, Bohdan Górski, Cezary Cybulski, Krzysztof Medrek, Marek Mierzejewski, Bartłomiej Masojc, Joanna Matyjasik, Elzbieta Złowocka, Urszula Teodorczyk, Marcin Lener, Ewa Klujszo-Grabowska, Katarzyna Nej-Wołosiak, Ewa Jaworowska, Dorota Oszutowska, Anna Szymańska, Jolanta Szymańska, Jennifer Castaneda, Thierry van de Wetering, Janina Suchy, Grzegorz Kurzawski, Oleg Oszurek, Steven Narod, Jan Lubinski.   

Abstract

The population frequencies of the CDKN2A common variants remain undetermined. In Poland, there is a common variant of the CDKN2A: an alanine to threonine substitution (A148T), which has been detected in other populations. We have recently showed that it is significantly overrepresented among Polish melanoma patients when compared to general population. Herein, we ascertained the prevalence of the A148T variant in 3,583 unselected cancer cases and 3,000 random control subjects from the same Polish population. We evaluated eleven different malignancies, representing the majority of all common cancer sites. Positive association with A148T variant was observed for lung cancer (OR, 2.0; p = 0.0052). A similar trend, although nonsignificant after the Bonferroni correction, was observed for colorectal cancer (OR, 1.5; p = 0.5499). These results suggest that A148T variant may be associated with a multi-organ cancer risk in the Polish population. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395703     DOI: 10.1002/ijc.21760

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.

Authors:  Bhramar Mukherjee; John Oliver Delancey; Leon Raskin; Jessica Everett; Joanne Jeter; Colin B Begg; Irene Orlow; Marianne Berwick; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Hoda Anton Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Lynn From; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

2.  Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

Authors:  Anne Guyot; Mathilde Duchesne; Sandrine Robert; Anne-Sophie Lia; Paco Derouault; Erwan Scaon; Leslie Lemnos; Henri Salle; Karine Durand; François Labrousse
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

3.  Bladder cancer survival in patients with NOD2 or CDKN2A variants.

Authors:  Elżbieta Złowocka-Perłowska; Thierry van de Wetering; Aleksandra Tołoczko-Grabarek; Rodney J Scott; Jan Lubiński
Journal:  Oncotarget       Date:  2022-04-22

4.  Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.

Authors:  Marta Heise; Piotr Jarzemski; Dagmara Nowak; Aneta Bąk; Anna Junkiert-Czarnecka; Maria Pilarska-Deltow; Maciej Borysiak; Beata Pilarska; Olga Haus
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

5.  Low-risk Genes and Multi-organ Cancer Risk in the Polish Population.

Authors:  Tadeusz Debniak; Cezary Cybulski; Grzegorz Kurzawski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Janina Suchy; Bartłomiej Masojć; Marek Mierzejewski; Marcin Lener; Urszula Teodorczyk; Krzysztof Medrek; Elzbieta Złowocka; Ewa Grabowska-Kłujszo; Katarzyna Nej-Wołosiak; Anna Szymańska; Jolanta Szymańska-Pasternak; Joanna Matyjasik; Thierry van de Wetering; Anna Jakubowska; Oleg Oszurek; Aleksandra Tołoczko-Grabarek; Jennifer Castaneda; Rodney Scott; Steven A Narod; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2006-01-15       Impact factor: 2.857

6.  Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia.

Authors:  Pablo Serrano-Fernandez; Dagmara Dymerska; Grzegorz Kurzawski; Róża Derkacz; Tatiana Sobieszczańska; Zbigniew Banaszkiewicz; Hanno Roomere; Eneli Oitmaa; Andres Metspalu; Ramūnas Janavičius; Pavel Elsakov; Mindaugas Razumas; Kestutis Petrulis; Arvīds Irmejs; Edvīns Miklaševičs; Rodney J Scott; Jan Lubiński
Journal:  Gastroenterol Res Pract       Date:  2015-05-26       Impact factor: 2.260

7.  Genetic polymorphisms may influence the vertical growth rate of melanoma.

Authors:  Mariusz Sikora; Lidia Rudnicka; Barbara Borkowska; Agnieszka Kardynał; Monika Słowińska; Adriana Rakowska; Olga Warszawik-Hendzel; Anna Wiergowska; Iwona Ługowska; Piotr Rutkowski; Tadeusz Dębniak; Jan Lubiński; Małgorzata Olszewska
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

8.  DNA testing for variants conferring low or moderate increase in the risk of cancer.

Authors:  Grzegorz Kurzawski; Janina Suchy; Cezary Cybulski; Joanna Matyjasik; Tadeusz Debniak; Bohdan Górski; Tomasz Huzarski; Anna Janicka; Jolanta Szymanska-Pasternak; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

9.  Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Authors:  Edyta Borkowska; Adam Jędrzejczyk; Andrzej Kruk; Michał Pietrusiński; Magdalena Traczyk; Marek Rożniecki; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2011-09-06

10.  Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.

Authors:  Takahisa Yamashita; Claudia Vollbrecht; Burkhard Hirsch; Karsten Kleo; Ioannis Anagnostopoulos; Michael Hummel
Journal:  J Clin Exp Hematop       Date:  2020
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.